Luminal markers, commonly used as an expression array signature for ER-positive breast cancers, showed no significant relationship with age cohort, ERBB2 status or PR status, although there was a nonsignificant trend for luminal gene expression to associate with PR-positive cases. The gene discussed is ERBB2; the disease is breast carcinoma.